|Grant Number:||5R01CA120594-05 Interpret this number|
|Primary Investigator:||Strasser, Andrew|
|Organization:||University Of Pennsylvania|
|Project Title:||Smoking Topography and Harm Exposure in a New Prep|
DESCRIPTION (provided by applicant): Approximately 25% of the adult US population are current smokers, and although many try to quit, most fail. As an alternative, some smokers use potentially reduced exposure products (PREPs). However, prior harm reduction products, such as light cigarettes, have proven to be a public health disaster. Carcinogen exposure studies and epidemiologic data show that compensatory smoking behavior can make light cigarettes as harmful as regular cigarettes. Therefore, it is important to understand how people use PREPs and to assess how this relates to their harm exposure. Quest(r) cigarettes are a new PREP that uses genetically modified tobacco to provide a "step-down approach to becoming nicotine-free" by marketing cigarettes with progressively lower levels of nicotine: 0.6 mg, 0.3 mg and 0.05 mg. The primary aim of the study is to investigate the effect of progressive decreases in cigarette nicotine level on smoking topography and harm exposure measures. The study will be a within-subject, open-label design of 210 smokers not currently interested in quitting. Participants will be randomized to one of three conditions: 1) continue to smoke their own brand (control); 2) smoke Quest(r) cigarettes in the step-down order, progressively decreasing cigarette nicotine level from 0.6 mg, to 0.3 mg, to 0.05 mg (Quest(r) step-down); or 3) smoke Quest(r) cigarettes in a non-step down random order, counter balanced across subjects (Quest(r) non-step- down). The study will consist of four stages beginning with a 5-day own brand cigarette smoking phase for all participants, followed by one of the three cigarette conditions. For those smoking Quest(r) cigarettes, cigarette nicotine level will change every 10 days, either in a step-down or random fashion. The primary behavioral outcome is smoking topography; specifically total and mean puff volume, which will be assessed at each session. Carbon monoxide to assess smoke exposure, and urinary biomarkers, will also be assessed. At baseline, participants will view Quest(r) advertisements and complete a survey of product expectations to determine the impact of beliefs about Quest(r) cigarettes on subsequent smoking behavior. This study has several important public health implications. It will determine how a new PREP is actually used. It will also determine how product use relates to harm exposure. Finally, it will identify those most susceptible to changes in smoking topography that may increase harm exposure.
Individual differences in positivity offset and negativity bias: Gender-specific associations with two serotonin receptor genes.
Authors: Ashare RL, Norris CJ, Wileyto EP, Cacioppo JT, Strasser AA
Source: Pers Individ Dif, 2013 Sep 1;55(5), p. 469-473.
The effect of menthol on cigarette smoking behaviors, biomarkers and subjective responses.
Authors: Strasser AA, Ashare RL, Kaufman M, Tang KZ, Mesaros AC, Blair IA
Source: Cancer Epidemiol Biomarkers Prev, 2013 Mar;22(3), p. 382-9.
EPub date: 2013 Jan 18.
Graphic warning labels in cigarette advertisements: recall and viewing patterns.
Authors: Strasser AA, Tang KZ, Romer D, Jepson C, Cappella JN
Source: Am J Prev Med, 2012 Jul;43(1), p. 41-7.
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.
Authors: Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA
Source: J Psychopharmacol, 2012 Oct;26(10), p. 1383-90.
EPub date: 2012 Jun 13.
Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study.
Authors: Ashare RL, Ray R, Lerman C, Strasser AA
Source: Drug Alcohol Depend, 2012 Nov 1;126(1-2), p. 263-7.
EPub date: 2012 May 15.